BeOne Medicines Ltd. (HKG:6160)

Market Cap	248.91B
Revenue (ttm)	35.81B
Net Income (ttm)	-1.39B
Shares Out	n/a
EPS (ttm)	-13.05
PE Ratio	n/a
Forward PE	96.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,526,521
Average Volume	7,060,699
Open	178.50
Previous Close	182.50
Day's Range	169.20 - 180.00
52-Week Range	103.10 - 190.80
Beta	0.27
RSI	48.60
Earnings Date	Aug 6, 2025

About The Duckhorn Portfolio

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

In 2024, BeOne Medicines's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in DKK